Ste. Marthe-sur-le-Lac, Canada

John Mancuso

This inventor holds 1 USPTO granted patent. Top assignee: Sail Biomedicines. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Mancuso. Retrieved from https://idiyas.com/inventor/john-mancuso-wayme7ic

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: John Mancuso and His Patent on AHR Antagonists.

Introduction

John Mancuso is an inventor based in Ste. Marthe-sur-le-Lac, Canada, and is associated with Sail Biomedicines. His patent work concerns compounds that may have applications in cancer treatment and disorders involving abnormal immune responses.

Latest Patents

Mancuso is associated with 1 patent: “Pyridopyrimidinone Derivatives as AHR Antagonists.” The disclosure covers compounds of formula (Ia), their pharmaceutically acceptable salts, pharmaceutical compositions, preparation methods, and useful intermediate compounds. It also describes potential methods for treating or preventing diseases, particularly cancer and conditions associated with dysregulated immune responses or aberrant AHR signaling. The compounds may also be investigated for use alongside at least one additional therapy.

Career Highlights

Mancuso’s listed patent activity connects his work with medicinal chemistry and therapeutic research. The patent describes a range of potential applications, including cancer treatment and conditions linked to AHR signaling.

Collaborations

The patent information names Alessandra Bartolozzi and John Robert Proudfoot among Mancuso’s coworkers. His company affiliation is Sail Biomedicines.

Conclusion

John Mancuso’s patent focuses on pyridopyrimidinone derivatives as AHR antagonists and outlines their potential role in treating cancer and other disorders associated with abnormal AHR signaling.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…